Shares of Hims & Hers Health Inc. are on track for their best week ever as a new partnership with Novo Nordisk A/S sends the telehealth company's stock surging. The collaboration focuses on weight-loss drugs, a rapidly growing market that has attracted intense investor interest. This marks a significant expansion of Hims' pharmaceutical offerings beyond its traditional men's and women's health products.

The partnership announcement comes at a time when demand for weight-loss medications has skyrocketed, with Novo Nordisk's GLP-1 drugs like Wegovy leading the charge. For Hims, entering this space represents a strategic pivot toward higher-margin pharmaceuticals and a potentially lucrative revenue stream. The company has been working to diversify beyond its core telehealth services and direct-to-consumer model.

Investors are clearly betting on the growth potential, pushing Hims shares to record levels this week. The weight-loss drug market is projected to reach $100 billion globally by 2030, making it an attractive target for telehealth companies looking to expand their prescription offerings. This partnership positions Hims to capture a share of that expanding market through its established digital platform and customer base.